Stock Events

Stock Events

Kala Bio 

€0.18
0
+€0.03+18.19% Today

Statistics

Day High
0.19
Day Low
0.19
52W High
16.42
52W Low
0.14
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

19NovExpected
Q3 2025
-0.88
-0.54
-0.21
0.12
Expected EPS
-0.8754175000000001
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 27F0.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap79.17B
Regeneron Pharmaceuticals competes in the ophthalmology space with treatments for eye diseases, directly competing with Kala's eye care products.
Novartis
NVS
Mkt Cap297.35B
Novartis offers a range of eye care medications, including treatments for conditions that Kala Bio targets, making them a direct competitor.
Abbvie
ABBV
Mkt Cap367.8B
AbbVie, through its acquisition of Allergan, has a strong presence in the ophthalmology market, competing with Kala Bio's eye care solutions.
Bausch Health Companies
BHC
Mkt Cap2.09B
Bausch Health Companies, formerly Valeant Pharmaceuticals, has a significant portfolio in eye health, competing in the same market as Kala Bio.
Biogen
BIIB
Mkt Cap25.38B
Biogen has a focus on specialty care and biologics that could compete with Kala Bio's treatments in certain niche markets.
Regenxbio
RGNX
Mkt Cap440.26M
REGENXBIO is a biotechnology company focused on the development of gene therapies for eye diseases, directly competing with Kala Bio's approach to eye care.
Gilead Sciences
GILD
Mkt Cap172.51B
Gilead Sciences, while primarily known for its work in antiviral drugs, has ventured into other therapeutic areas that could potentially compete with Kala Bio's niche markets.

About

Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.
Show more...
CEO
Dr. R. Kim Brazzell Ph.D.
Employees
38
Country
United States
ISIN
US4831192020

Listings

STU
DE
27F0.STU
MU
DE
27F0.MU
XNAS
US
KALA
LSE
GB
0JQ2.LSE

0 Comments

Share your thoughts

FAQ

What is Kala Bio stock price today?▼
The current price of 27F0.MU is €0.18 EUR — it has increased by +18.19% in the past 24 hours. Watch Kala Bio stock price performance more closely on the chart.
What is Kala Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Kala Bio stocks are traded under the ticker 27F0.MU.
Is Kala Bio stock price growing?▼
27F0.MU stock has risen by +28.52% compared to the previous week, the month change is a -26.57% fall, over the last year Kala Bio has showed a -94.28% decrease.
How many employees does Kala Bio have?▼
As of April 13, 2026, the company has 38 employees.
In which sector is Kala Bio located?▼
Kala Bio operates in the Health & Wellness sector.
When did Kala Bio complete a stock split?▼
Kala Bio has not had any recent stock splits.
Where is Kala Bio headquartered?▼
Kala Bio is headquartered in Arlington, United States.